NCT04640480 2026-01-27
Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors
SN BioScience
Phase 1 Completed
SN BioScience
Eastern Cooperative Oncology Group
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Merrimack Pharmaceuticals
Merrimack Pharmaceuticals
Vanderbilt-Ingram Cancer Center